CIMAher® · Nimotuzumab · Radiation Therapy · Comprehensive Oncology
Head & Neck Cancer Treatment in Cuba
Cuba's Center of Molecular Immunology (CIM) developed CIMAher (nimotuzumab), an anti-EGFR monoclonal antibody that has been extensively studied in head and neck cancers. Nimotuzumab is one of Cuba's most established immunotherapy agents for squamous cell carcinoma of the head and neck, used in combination with radiation therapy and chemotherapy. International patients access comprehensive head and neck cancer programs through SMC Salud's coordinated services in Havana.
Head & Neck Cancer — Treatment Video
Combating Cancer in Cuba — Head & Neck Oncology
Visual Guide
Understanding head & neck cancer care in Cuba
See the specialized facilities and patient-centered care that define our head & neck cancer treatment programs.
Specialized Oncology care in Cuba
Comprehensive international patient coordination in Havana
Clinical Evidence & Outcomes
The science behind head & neck cancer treatment in Cuba
Our clinical programs are grounded in peer-reviewed research and coordinated with Cuba's biotechnology institutions. Individual results vary and are confirmed during personalized evaluation.
CIMAher® (nimotuzumab)
Head and Neck Squamous Cell Carcinoma
Nimotuzumab is an anti-EGFR monoclonal antibody developed by Cuba's Center of Molecular Immunology. It has been extensively studied in head and neck squamous cell carcinoma, both as monotherapy and in combination with radiation therapy and chemotherapy. It is one of Cuba's most established immunotherapy applications for head and neck cancer.
Source: CIM — Center of Molecular Immunology
Combined Modality Therapy
Locally Advanced Head and Neck Cancer
Nimotuzumab is often used in combination with radiation therapy and chemotherapy for locally advanced head and neck cancer. The combination approach targets EGFR-expressing tumor cells while radiation and chemotherapy provide complementary cytotoxic effects. Treatment sequencing is determined by the multidisciplinary team.
Source: CIM — Center of Molecular Immunology
International Patient Coordination
Comprehensive Support
SMC Salud coordinates the full international patient pathway for head and neck cancer patients, including medical record review, treatment scheduling, and post-treatment telemedicine follow-up with the Cuban oncology team.
Source: SMC Salud — International Patient Services
Outcomes shown reflect published clinical data and aggregate results. Individual results vary based on diagnosis, disease stage, and overall health, and are confirmed during a personalized medical evaluation. This page is for educational purposes and is not a substitute for professional medical advice.
References & Citations
Clinical content on this page is supported by peer-reviewed research and institutional publications. Individual treatment outcomes vary and are confirmed during personalized medical evaluation.
- 1.
PubMed. Nimotuzumab in head and neck cancer clinical trials. National Library of Medicine.
PubMed - 2.
Center of Molecular Immunology (CIM). Nimotuzumab (CIMAher) development and clinical studies. Havana, Cuba.
- 3.
World Health Organization. Head and neck cancers fact sheet. WHO, 2024.
WHO Fact Sheet
Our Comprehensive Approach
CIMAher® (nimotuzumab)
Anti-EGFR monoclonal antibody developed by CIM, extensively studied in head and neck squamous cell carcinoma — one of Cuba's most established immunotherapy applications.
Comprehensive Evaluation
Oncology review of imaging, biopsy, HPV status, EGFR expression, and prior treatments to build a personalized plan.
Multidisciplinary Tumor Board
Surgical oncologists, radiation oncologists, medical oncologists, and ENT specialists collaborate on each case.
Radiation Therapy
Nimotuzumab is often used in combination with radiation therapy for locally advanced head and neck cancer.
Rehabilitation & Support
Speech and swallowing therapy, nutritional support, dental care, and psychological counseling.
International Patient Care
Full coordination: medical visa, accommodation, interpretation, and 24/7 support in Havana.
Head & Neck Cancer — Treatment & Medication
Treatment Options Available in Cuba
Cuba's CIMAher® (nimotuzumab) is one of the country's most established immunotherapy agents for head and neck squamous cell carcinoma, often used in combination with radiation therapy and chemotherapy. Treatment is coordinated by a multidisciplinary team. No therapy guarantees a cure, and not every patient will benefit. Treatment suitability is determined after medical evaluation of tumor location, stage, and overall health.
Treatment suitability is determined after medical evaluation. No therapeutic outcome is guaranteed, and not every patient will benefit. Each case is reviewed individually by the medical team.
Head & Neck Cancer — Required Documents
Documents for Medical Evaluation
Providing these documents helps our medical team review your case before you travel. You do not need to send every document to begin — send what you have available.
Biopsy / Pathology Report
Confirmed diagnosis and tumor type
CT / MRI / PET-CT
Recent imaging of head, neck, and staging
Oncology Reports
Specialist consultation and treatment notes
Previous Treatment Records
Surgery, radiation, or chemotherapy history
Current Medications
All medications currently being taken
Recent Laboratory Results
Blood work and tumor markers
Clinical Evidence
Patient Safety
Expert Specialists
International Standards
Frequently Asked Questions
Questions from international patients
Cuba offers comprehensive head and neck cancer treatment including CIMAher (nimotuzumab) immunotherapy, radiation therapy, chemotherapy, and surgical oncology. Nimotuzumab is one of Cuba's most established immunotherapy agents for head and neck squamous cell carcinoma, often used in combination with radiation therapy. The specific treatment plan is determined by the medical team after evaluation.
Find country-specific information, testimonials, and FAQs for your region.
Could This Treatment Be Right for You?
Submit your medical records for review by our medical team. We will assess your case and provide a personalized recommendation. Treatment suitability is determined only after medical evaluation.